News for ANL Stock

Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award Adlai Nortye Ltd. Announces Closing of Initial Public Offering Adlai Nortye Ltd. Announces Pricing of Initial Public Offering